EY Announces Liang Schweizer of HiFiBiO Therapeutics as an Entrepreneur Of The Year® 2024 New England Award Winner

Celebrating the bold leaders who disrupt markets, revolutionize industries and transform lives

CAMBRIDGE, Mass. – June 13, 2024 – Ernst & Young LLP (EY US) today announced that Liang Schweizer, PhD, CEO, Chairperson, and Founder of HiFiBiO Therapeutics was named an Entrepreneur Of The Year® 2024 New England Award winner. Entrepreneur Of The Year is the preeminent competitive awards program for entrepreneurs and leaders of high-growth companies.

Dr. Schweizer was selected by an independent judging panel made up of previous award winners, leading CEOs and other business leaders. Candidates were evaluated based on their ability to create long-term value through entrepreneurial spirit, commitment to their purpose and the demonstration of growth and substantial impact, among other key indicators.

“I am thrilled to be selected as a New England Award winner among many distinguished business leaders and entrepreneurs,” commented Dr. Schweizer, “This award is a recognition of the highly innovative and groundbreaking work being done at HiFiBiO Therapeutics to unlock the curative powers of the immune system for each and every patient. Our team works vigorously every day to advance our pipeline of breakthrough immunotherapies to transform patient lives. I am delighted and humbled to join the Entrepreneur Of The Year® community of inspiring business leaders.”

HiFiBiO Therapeutics is a clinical-stage US biotech company with a global footprint driving a robust pipeline of transformative immunotherapies targeting cancer and inflammation and immunology indications. Since its founding, the company has discovered and developed a diverse portfolio, including best-in-class and first-in-class therapies. Furthermore, the unique clinical approach guided by single cell powered Drug Intelligence Science (DIS®) platform provides insights into patient immunobiology and disease mechanisms to maximize clinical benefit. The company also embraces an open innovation model working with global partners to identify groundbreaking solutions for patients.

As a New England award winner, Dr. Schweizer is now eligible for consideration for the Entrepreneur Of The Year 2024 National Awards. The National Award winners, including the Entrepreneur Of The Year National Overall Award winner, will be announced in November at the Strategic Growth Forum®, one of the nation’s most prestigious gatherings of high-growth, market-leading companies. The Entrepreneur Of The Year National Overall Award winner will then move on to compete for the World Entrepreneur Of The Year® Award in June 2025.

Entrepreneur Of The Year recognizes many different types of business leaders for their ingenuity, courage and entrepreneurial spirit. The program celebrates original founders who bootstrapped their business from inception or who raised outside capital to grow their company; transformational CEOs who infused innovation into an existing organization to catapult its trajectory; and multigenerational family business leaders who reimagined a legacy business model to fortify it for the future.

The Entrepreneur Of The Year program has recognized the leadership of entrepreneurs such as:

  • Daymond John of FUBU
  • Hamdi Ulukaya of Chobani, Inc.
  • Holly Thaggard and Amanda Baldwin of Supergoop!
  • Howard Schultz of Starbucks Coffee Company
  • James Park of Fitbit
  • Jodi Berg of Vitamix
  • Kendra Scott of Kendra Scott LLC
  • Michael Happe of Winnebago Industries
  • Reid Hoffman and Jeff Weiner of LinkedIn Corporation
  • Sheila Mikhail of AskBio

Entrepreneur Of The Year Award winners become lifetime members of a global, multi-industry community of entrepreneurs. They receive exclusive, ongoing access to the experience, insight and wisdom of program alumni and other ecosystem members in more than 60 countries — all supported by vast EY resources.

In addition to Entrepreneur Of The Year, EY US supports other entrepreneurs through the EY Entrepreneurial Winning Women™(Winning Women) program and the EY Entrepreneurs Access Network (EAN) to help connect women founders and Black and Hispanic/Latino entrepreneurs, respectively, with the resources, network and access needed to unlock their full potential.

Sponsors

Founded and produced by Ernst & Young LLP, the Entrepreneur Of The Year Awards include presenting sponsors PNC Bank, Cresa, Marsh USA, SAP and the Ewing Marion Kauffman Foundation. In New England, sponsors also include a premier sponsor, DLA Piper.

 

About Entrepreneur Of The Year®

Founded in 1986, Entrepreneur Of The Year® has celebrated more than 11,000 ambitious visionaries who are leading successful, dynamic businesses in the US, and it has since expanded to nearly 80 countries and territories globally.

The US program consists of 17 regional programs whose panels of independent judges select the regional award winners every June. Those winners compete for national recognition at the Strategic Growth Forum® in November where National finalists and award winners are announced. The overall National winner represents the US at the World Entrepreneur Of The Year® competition. Visit ey.com/us/eoy.

About EY

EY exists to build a better working world, helping to create long-term value for clients, people and society and build trust in the capital markets.

Enabled by data and technology, diverse EY teams in over 150 countries provide trust through assurance and help clients grow, transform and operate.

Working across assurance, consulting, law, strategy, tax and transactions, EY teams ask better questions to find new answers for the complex issues facing our world today.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.

About HiFiBiO Therapeutics

HiFiBiO Therapeutics is a clinical-stage US biotech with a global footprint driving a robust clinical pipeline of transformative immunotherapies targeting cancer and autoimmune diseases.  HiFiBiO achieves an unprecedented understanding of immune modulation in human diseases by pioneering a unique high-resolution translational platform, Drug Intelligence Science (DIS®), which combines unique single-cell capabilities with AI/ML approaches.  Using patient samples, DIS® enables the discovery of novel targets, effective antibody drugs, and predictive biomarkers to enhance the probability of success for immunotherapies. Moreover, HiFiBiO has established partnerships with major multinational pharmaceutical and biotech companies and has been recognized as one of the 2023 Fierce 15 biotech companies. For additional information, please visit www.hifibio.com